Drug intelligence / Profile preview

SAL0120

Development stage: Phase 3
Lead developer: Shenzhen Salubris Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

SAL0120 is a small molecule endothelin receptor type A (ETA) antagonist being developed by Shenzhen Salubris Pharmaceuticals for the treatment of hypertension and chronic kidney disease (CKD). The drug is formulated as an oral tablet and is currently in Phase 2 clinical development. Its mechanism of action involves the selective antagonism of the ETA receptor, which plays a critical role in mediating vasoconstriction, cellular proliferation, and fibrosis. By blocking this receptor, SAL0120 aims to lower blood pressure and provide renoprotective effects in patients with uncontrolled hypertension or CKD.

Targets

EDNRA (Endothelin receptor type A)

Beyond the preview

Go deeper on SAL0120.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SAL0120.

Explore the full profile